New molecular and immunotherapeutic approaches in biliary cancer

被引：31

作者：

Goldstein, David ^{[1
,2
]}

Lemech, Charlotte ^{[1
,2
]}

Valle, Juan ^{[3
,4
]}

机构：

[1] Prince Wales Hosp, Nelune Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia

[2] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia

[3] Univ Manchester, Inst Canc Studies, Manchester, Lancs, England

[4] Christie NHS Fdn Trust, Manchester, Lancs, England

来源：

ESMO OPEN | 2017年 / 2卷

关键词：

PHASE-II TRIAL; TRACT CANCER; OPEN-LABEL; GALLBLADDER CARCINOMA; PLUS SORAFENIB; GEMCITABINE; COMBINATION; OXALIPLATIN; CETUXIMAB; MULTICENTER;

D O I：

10.1136/esmoopen-2016-000152

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biliary tract carcinoma is a collective term for a group of rare gastrointestinal cancers. This overview outlines the key pathways and specialised therapeutics in biliary cancer and the emerging role of immunotherapy by highlighting the rationale and selected examples of studies in each area.

引用

页数：9

共 72 条

[1] Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer [J].

Ahn, Daniel H. ;

Li, Junan ;

Wei, Lai ;

Doyle, Austin ;

Marshall, John L. ;

Schaaf, Larry J. ;

Phelps, Mitch A. ;

Villalona-Calero, Miguel A. ;

Bekaii-Saab, Tanios .

SCIENTIFIC REPORTS, 2015, 5

[2] Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours. [J].

Ahnert, Jordi Rodon ;

Garratt, Chris ;

Laapas, Kaisa ;

Leskinen, Hanna ;

Bjorklund, Harry ;

Ruck, Angela ;

Peltola, Katriina ;

Azaro, Analia ;

Castanon-Alvarez, Eduardo ;

Massard, Christophe ;

Bono, Petri .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[3]

[Anonymous], 2016, J CLIN ONCOL S

[4] Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028 [J].

Bang, Y. J. ;

Doi, T. ;

De Braud, F. ;

Piha-Paul, S. ;

Hollebecque, A. ;

Razak, A. R. Abdul ;

Lin, C. C. ;

Ott, P. A. ;

He, A. R. ;

Yuan, S. S. ;

Koshiji, M. ;

Lam, B. ;

Aggarwal, R. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S112-S112

[5] Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers [J].

Bekaii-Saab, Tanios ;

Phelps, Mitch A. ;

Li, Xiaobai ;

Saji, Motoyasu ;

Goff, Laura ;

Kauh, John Sae Wook ;

O'Neil, Bert H. ;

Balsom, Stephanie ;

Balint, Catherine ;

Liersemann, Ryan ;

Vasko, Vasily V. ;

Bloomston, Mark ;

Marsh, William ;

Doyle, L. Austin ;

Ellison, Gilian ;

Grever, Michael ;

Ringel, Matthew D. ;

Villalona-Calero, Miguel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2357-2363

[6] Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial [J].

Bengala, C. ;

Bertolini, F. ;

Malavasi, N. ;

Boni, C. ;

Aitini, E. ;

Dealis, C. ;

Zironi, S. ;

Depenni, R. ;

Fontana, A. ;

Del Giovane, C. ;

Luppi, G. ;

Conte, P. .

BRITISH JOURNAL OF CANCER, 2010, 102 (01) :68-72

[7] Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology [J].

Borbath, I. ;

Ceratti, A. ;

Verslype, C. ;

Demols, A. ;

Delaunoit, T. ;

Laurent, S. ;

Deleporte, A. ;

Vergauwe, P. ;

Van Maanen, A. ;

Sempoux, C. ;

Van Cutsem, E. ;

Van Laethem, J. L. .

ANNALS OF ONCOLOGY, 2013, 24 (11) :2824-2829

[8]

BRIDGEWATER J, 2016, BMC CANCER, V16

[9]

Bridgewater John A, 2016, Am Soc Clin Oncol Educ Book, V35, pe194, DOI 10.14694/EDBK_160831

[10]

Burris H, 2015, MOL CANC THER S2, V14

← 1 2 3 4 5 6 7 8 →